Retrogenix joins forces with Medicines Discovery Catapult & Peak Proteins in the race to develop a treatment for COVID-19

Retrogenix has entered a new collaboration with Medicines Discovery Catapult and Peak Proteins to advance the understanding of the cellular mechanisms of infection by COVID-19. This research aims to uncover any unknown cellular receptors or binding proteins of the COVID-19 coronavirus on human cells.

Identification of such receptors could provide the basis for new therapeutic approaches to counter the current global coronavirus pandemic, and may guide drug re-purposing efforts.

How can our cell microarray platform advance understanding of COVID-19?

Retrogenix’s unique cell microarray technology provides a fast, accurate solution for discovering the human cell surface and secreted protein targets of viruses, antibodies, proteins, CAR-T cells and small molecules.

Our unique tool uses proprietary arrays of expression vectors – encoding over 5,900 full-length human plasma membrane, tethered secreted, and heterodimer proteins – spotted onto slides. Human cells grown over the top become reverse-transfected, resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.

Jo Soden, Co-founder and Director at Retrogenix, says:

By screening against our unique library of human cell surface proteins, Retrogenix has previously been highly successful in identifying viral receptors. Using the same technology, we now have the perfect opportunity to search for new receptors for COVID-19.

A positive find could have significant consequences in the search for treatments.

If you’d like to stay informed as further information is released regarding this COVID-19 research, please chose the option which suits you best:

Or please feel free to get in touch with us using the form.

Our proprietary cell microarray technology uncovers high quality, exploitable drug targets, as well as identifying potential off targets to inform lead selection and assist with safety assessment. Our data is used in many successful IND submissions. Learn more:

Stay informed on this research
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
glycotope_logo
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Capella Bioscience Logo
Sanofi Logo
Unum Theraputics Logo
Celyad Logo